Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction

Journal of Thrombosis and Thrombolysis

Volumn 29, Issue 4, 2010, Pages 421-428

  Weir, Robin A P ^a   Balmain, Sean ^a   Steedman, Tracey ^a   Ng, Leong L ^b   Squire, Iain B ^b   Rumley, Anne ^c   Dargie, Henry J ^a   Lowe, Gordon D O ^c  

^a WESTERN INFIRMARY   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cardiac magnetic resonance; Myocardial infarction; Tissue plasminogen activator antigen; Von Willebrand factor

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GELATINASE A; GELATINASE B; STROMELYSIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR; ALDOSTERONE ANTAGONIST; BIOLOGICAL MARKER; DRUG DERIVATIVE; EPLERENONE; MATRIX METALLOPROTEINASE; SPIRONOLACTONE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HEART INFARCTION; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL;

AGED; ALDOSTERONE ANTAGONISTS; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; SPIRONOLACTONE; STROKE VOLUME; TISSUE PLASMINOGEN ACTIVATOR; VENTRICULAR REMODELING; VON WILLEBRAND FACTOR;

EID: 77955498500     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0383-6     Document Type: Article

References (32)

1. Lowe GD, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH (2004) Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 25(3):252-259
2. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG (1996) Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT study group. European concerted action on thrombosis and disabilities. Circulation 94(9):2057-2063
3. Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, Choussat R, Beygui F, Borentain M, Vignolles N, Thomas D (2003) Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 108(4):391-394
4. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP, Bigonzi F, Thomas D (1998) Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE trial. Circulation 98(4):294-299
5. Sosin MD, Bhatia G, Davis RC, Lip GY (2003) Congestive heart failure and Virchow's triad: a neglected association. Wien Med Wochenschr 153 (19-20): 411-416
6. El-Menyar AA, Altamimi OM, Gomaa MM, Dabdoob W, Abbas AA, Abdel Rahman MO, Bener A, Albinali HA (2006) Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction. Coron Artery Dis 17(5):431-437
7. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA (1997) Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART study investigators. Circulation 96(2):442-447
8. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaître V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D (1997) Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17(4):439-444
9. Tziakas DN, Chalikias GK, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI, Kaski JC (2005) N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Am J Cardiol 96(1):31-34
10. Weir RA, Mark PB, Petrie CJ, Clements S, Steedman T, Ford I, Ng LL, Squire IB, Wagner GS, McMurray JJ, Dargie HJ (2009) Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am Heart J 157(6):1088-1096
11. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the American heart association. Circulation 105(4):539-542
12. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ (1987) Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76(1):44-51
13. Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ, Squire IB (2008) Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 10(2):133-139
14. Booth NA (1999) Fibrinolysis and thrombosis. Baillieres Best Pract Res Clin Haematol 12(3):423-433
15. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European concerted action on thrombosis and disabilities angina pectoris study group. N Engl J Med 332(10):635-641
16. De Bono D (1994) Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 71(6):504-507
17. Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM, CADET Study Investigators (2004) A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost 2(11):1934-1940
18. Jansson JH, Nilsson TK, Johnson O (1998) von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 80(4):334-337
19. Takeshita K, Hayashi M, Iino S, Kondo T, Inden Y, Iwase M, Kojima T, Hirai M, Ito M, Loskutoff DJ, Saito H, Murohara T, Yamamoto K (2004) Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol 164(2):449-456
20. Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY (2003) Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis 14(6):515-521
21. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY (2004) Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110(13):1794-1798
22. Chong AY, Freestone B, Patel J, Lim HS, Hughes E, Blann AD, Lip GY (2006) Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 97(5):671-675
23. Pawlowska Z, Jerczyńska H, Szemraj J, Barańska P, Swiatkowska M, Cierniewski CS (2002) Natriuretic peptides reduce plasminogen activator inhibitor-1 expression in human endothelial cells. Cell Mol Biol Lett 7(4):1153-1157
24. Yoshizumi M, Tsuji H, Nishimura H, Masuda H, Kunieda Y, Kawano H, Kimura S, Sugano T, Kitamura H, Nakagawa K, Nakagawa M (1999) Natriuretic peptides regulate the expression of tissue factor and PAI-1 in endothelial cells. Thromb Haemost 82(5):1497-1503
25. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345(14):1014-1021
26. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG (2003) B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107(22):2786-2792
27. Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, Daikoku S, Matsumoto T, Miyazaki S, Matsuoka H, Takishita S, Kangawa K, Matsuo H, Nonogi H (1998) Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 135(1):21-28
28. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM (2004) Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 10(4):328-333
29. Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, Squire IB (2007) Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 28(6):711-718
30. Jones CB, Sane DC, Herrington DM (2003) Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 59(4):812-823
31. Tziakas DN, Chalikias GK, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI, Kaski JC (2006) Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction. Thromb Res 118(2):221-227
32. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ (2000) Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2(4):271-278